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Summary 
 
Understanding the mechanisms by which cells 
coordinate their size with their ability to divide has long 
attracted the interest of biologists. The Target of 
Rapamycin (TOR) pathway is becoming increasingly 
recognized as a master regulator of cell size, however less 
is known how TOR activity might be coupled with the cell 
cycle. Here, we establish that mTOR complex 1 
(mTORC1) promotes cytokinesis through activation of a 
Rho GTPase-Rho Kinase (ROCK) signaling cascade. 
Hyperactivation of mTORC1 signaling by depletion of any 
of its negative regulators: TSC1, TSC2, PTEN, or 
DEPTOR, induces polyploidy in a rapamycin-sensitive 
manner. mTORC1 hyperactivation-mediated 
polyploidization occurs by a prolonged, but ultimately failed 
attempt at abcission followed by re-fusion. Similar to the 
effects of ROCK2 overexpression, these mTORC1-driven 
aberrant cytokinesis events are accompanied by increased 
Rho-GTP loading, extensive plasma membrane blebbing, 
and increased actin-myosin contractility, all of which can 
be rescued by either mTORC1 or ROCK inhibition. These 
results provide evidence for the existence of a novel 
mTORC1-Rho-ROCK pathway during cytokinesis and 
suggest that mTORC1 might play a critical role in setting 
the size at which a mammalian cell divides.  
 
Introduction 
 
 Key to the proper transition of cells through the 
cell cycle is their passage through multiple signaling 
‘checkpoints’. One of the first insights into the existence 
and function of one of these checkpoints was the isolation 
and characterization of a mutation in the Wee1 gene. 
Wee1 mutant cells were shown to abrogate a previously 
unknown to exist cell size checkpoint strikingly, undergoing 
cell division at half the size of wild-type cells (1). Since this 
discovery, our understanding of the mechanisms 
controlling cell size and cell division have rapidly, though 
separately, evolved. The Rho pathway has emerged as a 
central player in controlling the actin-myosin-based 
contractile events required for cytokinesis (2, 3). 
Regarding the regulation of cell size, the TOR signaling 
pathway has received considerable attention, in particular 
for its role in controlling the G1 growth phase of the cell 
cycle. Though it has largely become known as a controller 
of protein synthesis and the G1 program, it has also long 
been clear that TOR has a second, distinct essential 
function involving the cell-cycle dependent organization of 
the cytoskeleton (4). Mutations in TOR2 do not arrest cells 
in G1 as is the case with rapamycin treated cells, but 
rather cause arrest at multiple points in the cell cycle (5) 
accompanied by profound actin cytoskeletal 
disorganization (4). That the lethality of a TOR2 mutation 
could be rescued by overexpression of components of the 
Rho pathway hinted at the relationship between these 
pathways during the cell cycle (6). However, the 
importance of such a coupling during cell division still 
remains largely unknown. To address this question, we 
have investigated the involvement of mTOR signaling in 
cytokinesis. We find that mTORC1 hyperactivation causes 
prolonged cytokinesis due to Rho-ROCK hyperactivity and 
is associated with increased polyploidy, a condition 
thought to underlie the malignancy of certain cancers.  
 
Results 
The mTOR pathway is repressed through the actions of 
multiple upstream inhibitory proteins including TSC1, 
TSC2, PRAS40, PTEN, and REDD1 (7). We recently 
identified a novel negative regulator of the mTOR pathway, 
DEPTOR, which binds mTOR and inhibits both mTORC1 
and mTORC2 signaling pathways (8). In characterizing 
DEPTOR function, we noticed that its depletion in cells by 
RNAi promoted their multinucleation (Fig. 1A). To quantify 
this phenomenon, we measured the DNA content of 
DEPTOR knockdown cells compared with control cells. 
The results were clear; DEPTOR knock-down increased 
the percentage of 8N cells relative to those of control 
knockdown cells (Fig. 1B). Because DEPTOR depletion 
activates both the mTORC1 and mTORC2 pathways, we 
sought to determine whether either of these pathways 
might be responsible for mediating the effects of DEPTOR 
on ploidy. First, we knocked down known regulators of 
mTORC1 and/or mTORC2: raptor, rictor, mTOR, TSC1, 
TSC2, and PTEN and measured their DNA content. 
Similar to that of DEPTOR knockdown cells, cells with 
knockdown of any of the negative regulators of mTOR: 
TSC1, TSC2, or PTEN increased the percentage of 8N 
cells relative to control knockdown cells (Fig. 1B). Fittingly, 
the increased >4N DNA content of TSC1 knockdown was 
similar to those seen in a different cell type with complete 
loss of TSC1 (9). That neither mTORC1 nor mTORC2 
inactivation by knockdown or raptor or rictor, respectively 
increased the percentage of 8N cells is consistent with 
DEPTOR being a negative regulator of mTOR signaling 
(Fig. 1B). Finally, treatment of DEPTOR or TSC2 knock-
down cells with rapamycin, which only significantly inhibits 
mTORC1 and not mTORC2 in the cells we assessed (8), 
fully reduced the percentage of 8N cells (Fig. 1B) 
suggesting that deregulation of mTORC1 is responsible for 
effects of mTOR on polyploidy. 
 To explore at which point in their cell cycle 
mTORC1-hyperactivated cells became polyploid, we 
visually monitored individual knockdown cells over time. 
Both wild-type and DEPTOR knockdown cells progressed 
through interphase and through early stages of mitosis 
similarly (Fig. 2A). However, upon daughter cell 
separation, the surface of DEPTOR knockdown cells, 
unlike control cells, began to bleb massively and this was 
subsequently followed after a prolonged period of blebbing 
by fusion of their membranes and the creation of one cell 
containing both daughter nuclei (Fig. 2A). The same 
prolonged period of surface blebbing pattern was also 
observed in cells deficient in TSC1, TSC2, or PTEN but 
not in rictor knockdown cells (Fig. 2B-C) suggesting that 
blebbing-associated multinucleation is due to 
hyperactivation of mTORC1 and not mTORC2 (either 
directly or indirectly through the well-characterized 
mTORC1-PI3K feedback loop(10)). To strengthen the 
claim that this aberrant surface blebbing was mediated by 
mTORC1, we treated DEPTOR knock-down cells with 
rapamycin immediately preceding the point at which they 
began to separate into two daughter cells. Rapamycin 
treatment dramatically reduced the time required for the 
separation of DEPTOR-deficient daughter cells as well as 
the time of their surface blebbing (Fig. 2B, 2D). Correlating 
with the degree of polyploidy, these results suggest that 
surface blebbing-associated cytokinesis defects in 
DEPTOR deficient cells are the result of mTORC1 
hyperactivation. During cytokinesis, cytoskeletal 
rearrangements are critical for physically separating cells 
after their duplication (11). Both microtubules and the actin 
Fig. 1. mTORC1 hyperactivation causes polyploidy. (A) HeLa 
cells were infected with lentivirus expressing shRNAs targeting 
DEPTOR or GFP. Cells were processed in an immunofluorescence 
assay to detect α-tubulin (green), costained with DAPI for DNA 
content (blue), and imaged. (B) HeLa cells pretreated with 100nM 
rapamycin or vehicle were infected with lentivirus expressing the 
indicated shRNAs, stained with propidium iodide, and analyzed for 
DNA content by flow cytometry. > 20,000 cells were analyzed for 
each condition. Error bars indicate standard error for n=3.  
	  
are core components of the cytoskeleton driving this 
process (11), therefore we assessed their morphology with 
or without mTORC1 hyperactivation during multiple stages 
of cell cycle. Control and DEPTOR knockdown cells had 
similar cortical actin positioning and assembly of their α-
tubulin-containing spindles in mitosis (Fig. 2E). However, 
in cytokinesis, while control daughter cells had 
symmetrical actin cortices, in DEPTOR depleted cells, 
their actin architecture was grossly disorganized and 
appeared to be forming blebbing patterns similar to that 
which we observed in DEPTOR depleted cells by light 
microscopy (Fig.2A-B, 2E).  
 Actin-myosin contractility provides critical 
mechanical force to promote cell cleavage in cytokinesis 
and is known to be coordinated by many Rho-GTP-
dependent kinases which regulate this contractility by 
phosphorylating myosin light chain 2 (MLC2) (12). To test 
a role for mTORC1 in regulating actin-myosin contractility, 
we first confirmed in our cell system that the MLC2 
phosphorylating kinase, Rho kinase 2 (ROCK2), regulates 
the morphology of the actin cytoskeleton (13). While 
overexpression of kinase dead ROCK2 did not strongly 
perturb the actin cytoskeleton compared with 
overexpression of a control protein, overexpression of 
wild-type ROCK2 produced strong actin blebbing much 
like that we had seen with DEPTOR knockdown cells (Fig. 
2E). As expected, ROCK2 overexpression also increased 
S19 MLC2 phosphorylation (Fig. 3A). To test whether 
DEPTOR regulated ROCK signaling during cytokinesis, we 
measured MLC2 phosphorylation in DEPTOR and control 
knockdown cells. Typical of metazoan cells in cytokinesis, 
we detected prominent S19 MLC2 phosphorylation in 
control cells that was reduced by inhibition of ROCK 
activity (Fig. 3B) (14, 15). On the other hand, DEPTOR 
depleted cells, had substantially elevated levels of S19 
MLC2 phosphorylation compared with control cells (Fig. 
3C). That the effects of DEPTOR loss of S19 MLC2 
phosphorylation were strongly reduced by ROCK inhibition 
(Fig. 3B) suggests that DEPTOR loss activates ROCK 
signaling. 
 Because it is possible that DEPTOR knockdown 
activates ROCK signaling independent of its effects on 
mTORC1, we tested whether mTORC1 inhibition would 
reverse the effects of DEPTOR depletion on MLC2 
phosphorylation. Indeed, treating DEPTOR knockdown 
cells with either rapamycin or a concentration of Torin1 
which only potently inhibits mTORC1 signaling (8) reduced 
S19 MLC2 phosphorylation (Fig. 3C). We next sought to 
determine whether the effects of DEPTOR on ROCK 
Fig. 2. mTORC1 hyperactivation distorts the actin cytoskeleton 
and prolongs cytokinesis. 
(A) and (B) HeLa cells were infected with lentivirus expressing 
shRNAs targeting DEPTOR, TSC2, or GFP were analyzed by light 
microscopy (10x). Images were captured once per minute. (C) and 
(D) All images from (A) and (B) were visually inspected and manually 
counted to determine the % of cells blebbing and time of blebbing in 
minutes. > 50 cells were analyzed for each sample. Error bars 
indicated standard error for n=3. (E) HeLa cells were infected with 
lentivirus expressing a shRNA targeting DEPTOR or GFP. Cells were 
then processed in an immunofluorescence assay to detect α-tubulin 
(green), actin (red), costained with DAPI for DNA content (blue), and 
imaged.	  
activity were direct. Because ROCK is activated by binding 
to the active, GTP-bound form of Rho (16) and because 
TOR is known to regulate Rho GEF activity (6), we tested 
whether DEPTOR knockdown regulates ROCK by altering 
the Rho-GTP/GDP state. DEPTOR knockdown cells had 
higher levels of Rho-GTP than control cells and this 
increased activity was reduced by rapamycin (Fig. 3D). 
These results are consistent with mTORC1 activating 
ROCK upstream of ROCK itself by promoting Rho activity. 
Because ROCK directly phosphorylates many substrates 
besides MLC2, we checked whether other ROCK outputs 
were also regulated by manipulation of mTORC1. Mypt1 is 
the targeting subunit for the S19 MLC2 phosphatase and 
is known to be inhibited in its activity by phosphorylation at 
its T696 site by ROCK (17, 18). DEPTOR knockdown 
increased and mTOR knockdown decreased Mypt1 T696 
phosphorylation consistent with mTORC1 positively 
regulating ROCK activity toward this substrate (Fig. 3E). 
Another target of ROCK pathway is Cofilin. Cofilin is an F-
actin severing protein which is inhibited through its S3 
phosphorylation by the ROCK-activated kinase, LIMK1 
(19). Consistent with the effects of DEPTOR knockdown 
on MLC2 and Mypt1 phosphorylation, S3 cofilin 
phosphorylation was increased by DEPTOR knockdown 
above the levels seen in control knockdown in multiple cell 
types (Fig. 3F). In total, these results suggest that Rho-
ROCK signaling toward multiple effector pathways is 
positively regulated by mTORC1. 
 To better define how DEPTOR-mTORC1 controls 
Rho-ROCK activity, we assessed DEPTOR localization in 
cells undergoing cytokinesis. We detected DEPTOR 
throughout the cell, though it was clearly enriched at the 
centrosomes and the cleavage furrow, two subcellular 
localizations, which interestingly are also enriched for 
ROCK and RhoA, respectively (Fig. 4A) (20, 21). 
Previously, we have shown that DEPTOR phosphorylation 
state and levels are regulated by growth factors in an 
mTOR-dependent manner (8), therefore we assessed 
whether DEPTOR was also regulated in a cell cycle-
dependent manner. Arresting cells in mitosis with 
nocodazole, a microtubule disrupting agent (22), 
significantly impaired the gel mobility of the DEPTOR 
protein, and this gel mobility was restored when 
nocodazole was removed from the media (Fig. 4B). This 
suggests that DEPTOR might be regulated by 
phosphorylation during completion of the cell cycle. 
Because DEPTOR phosphorylation is known to regulate 
its ability to repress mTOR signaling (8), we wanted to 
determine we might be able to overcome this reduction in 
DEPTOR function during cytokinesis by inducing its 
overexpression. To do this, we measured histone 
phosphorylation, which regulates and provides a 
Fig. 3. mTORC1 hyperactivation activates Rho-ROCK signaling. 
(A) HEK-293T cells transfected with the indicated cDNAs were 
analyzed by immunoblotting for S19 MLC2 phosphorylation. (B) HeLa 
cells were infected with lentivirus expressing shRNAs targeting 
DEPTOR or GFP, treated for 10 minutes with 10µM of Y-27632 or 
vehicle, and processed in an immunofluorescence assay to detect α-
tubulin (green), S19 MLC2 phosphorylation (red), costained with 
DAPI for DNA content (blue), and imaged. (C) HeLa cells were 
infected with lentivirus expressing shRNAs targeting DEPTOR or 
GFP, treated for 10 minutes with 100nM rapamycin, 50µM Torin1, 
10µM of Y-27632, or vehicle and processed in an 
immunofluorescence assay to detect S19 MLC2 phosphorylation and 
imaged. (D) HeLa cells were infected with lentivirus expressing 
shRNAs targeting DEPTOR or GFP, treated for 10 minutes with 
100nM rapamycin or vehicle, immunoprecipitation of Rhotekin 
binding proteins was performed, and immunoprecipitates and lysates 
were analyzed by immunoblotting for the indicated levels of the 
specified proteins. (E) HeLa cells were infected with lentivirus 
expressing the indicated shRNAs were analyzed by immunoblotting 
for the phosphorylation states of the specified proteins. (F) Indicated 
p53-/- MEFs were generated and analyzed as in (E). 
	  
convenient marker of mitotic progression (23). While 
nocodazole increased the percentage of phosphorylated 
S10 Histone H3 (p-H3) positive control and DEPTOR 
overexpressing cells similarly, release from mitotic arrest 
was slower in DEPTOR overexpressing cells than control 
cells (Fig. 4C-D). In summary, this data suggests that 
DEPTOR is regulated both post-translational and by 
localization during the later stages of the cell cycle and 
that inactivation or hyperactivation of mTORC1 signaling 
both prolong the time necessary to complete cytokinesis. 
   
 
Discussion 
 
Here we find that increased mTORC1 causes 
polyploidy due to defective cytokinesis that is correlated 
with increased Rho-ROCK-mediated phosphorylation of 
multiple effectors including MLC2, Mypt1, and Cofilin. 
While there is some evidence that mTOR regulates Rho-
dependent processes in mammalian cells (24, 25), our 
work, to our knowledge, is the first to demonstrate that 
mTORC1 regulates cytokinesis via activation of Rho-
ROCK signaling. One question still remaining is whether 
mTORC1 and not mTORC2 controls all mTOR-dependent, 
Rho signaling processes. Recently, it has been argued 
that, on the contrary, many of the effects of mTOR on the 
actin cytoskeleton are due to regulation of TORC2 and not 
TORC1 signaling (24). While our work does not directly 
address these claims, there is precedence with other TOR-
dependent outputs that TORC1 and TORC2 might overlap 
in function more than is readily appreciated. In yeast, Sch9 
is a target of TORC1 and controls longevity in a manner 
analogous to one of its homologs in higher organisms, Akt, 
which is an mTORC2, and not mTORC1, substrate (26-
28). Also, loss-of-function alleles of LST8, a component of 
both TORC1 and TORC2, regulates rapamycin-sensitive, 
GAP1 permease sorting in yeast, but in mammals, does 
not only significant impair mTORC1 function and rather is 
essential for mTORC2-Akt activity (29, 30).  
Future studies will undoubtedly be needed to 
better understand the mechanisms by which TOR 
regulates Rho function. Recently, it has been shown that 
rapamycin downregulates the translation of ROCK1(31). 
Whereas, our data suggests that mTORC1 also regulates 
the Rho pathway upstream of ROCK (Fig. 3E). Because 
TOR is known to regulate numerous effectors by their 
phosphorylation (32), one interesting possibility stemming 
from our work is to test whether mTORC1 regulates the 
phosphorylation state of a Rho-GAP or Rho-GEF. By 
answering this as well as other questions of how TOR and 
Rho work, it is exciting to consider that understanding of 
one of biology’s central questions ‘how cell size is 
coordinated with cell division’ will be closer in reach. 
 
Fig. 4. Further characterization of DEPTOR during cytokinesis. 
(A) HeLa cells were processed in an immunofluorescence assay to 
detect DEPTOR (green), costained with DAPI for DNA content (blue), 
and imaged. (B) HeLa cells were treated with 100ng/µl nocodazole or 
vehicle for 16 hours and released for the indicated times, cell lysates 
were prepared and analyzed by immunoblotting for DEPTOR or 
mTOR. (C) and (D) HeLa cells treated as in (B) were processed in an 
immunofluorescence assay to detect phosphorylated S10 Histone H3 
(pink), myc-DEPTOR (green), costained with DAPI for DNA content 
(blue), and imaged. Three images for each condition were analyzed 
by image analysis software (CellProfiler) and mean measurements 
are shown in (C). Representative images are shown in (D). (E) 
Depiction of mTORC1-DEPTOR activity during the cell cycle.	  
Experiments in Figure 1 were performed by T.R.P. 
Experiments in Figure 2 were performed by T.R.P. and 
assisted by E.V.  
Experiments in Figure 3 were performed by T.R.P. 
Experiments in Figure 4 were performed by T.R.P. 
 
Experimental procedures 
 
Materials 
Reagents were obtained from the following sources: Rho 
Assay Reagent (Rhotekin RBD agarose), and antibodies 
to DEPTOR, raptor, Rho, phospho-T696 Mypt1 from 
Millipore; mouse monoclonal DEPTOR antibody from 
Novus Biologicals; antibodies to phospho-S10 Histone H3, 
mTOR, actin, as well as HRP-labeled secondary 
antibodies from Santa Cruz Biotechnology; antibodies to 
mTOR, phospho-S19 MLC2, phospho-S3 Cofilin, Cofilin, 
and the c-MYC epitope from Cell Signaling Technology; α-
tubulin antibodies, Y-27632, and nocodazole from Sigma 
Aldrich; DMEM from SAFC Biosciences; rapamycin from 
LC Labs; PreScission protease from Amersham 
Biosciences; pTREQ Tet-On vector from Clontech; 
FuGENE 6 and Complete Protease Cocktail from Roche; 
Alexa Fluor 488 and 568 Phalloidin, Propidium Iodide, and 
inactivated fetal calf serum (IFS) from Invitrogen. Torin1 
was kindly provided by Nathaniel Gray (Harvard medical 
School).  
 
Cell Lines and Cell Culture 
HeLa, HEK-293T, and MEFs were cultured in DMEM with 
10% Inactivated Fetal Bovine Serum (IFS). p53-/- MEFs 
were kindly provided by David Kwitakowski (Harvard 
Medical School). The HeLa cell line with doxycycline-
inducible DEPTOR expression was generated by retroviral 
transduction of HeLa that were previously modified to 
express rtTA with an inducible DEPTOR cDNA (8).   
  
cDNA Manipulations, Mutagenesis, and Sequence 
Alignments 
The cDNAs for DEPTOR and metap2 was previously 
described. The cDNA for full-length wild-type ROCK2 was 
kindly provided by K. Kaibuchi (33). 
 
Mammalian Lentiviral shRNAs 
Lentiviral shRNAs to the indicated human and mouse 
genes were previously described (8, 28) .  
 
shRNA-encoding plasmids were co-transfected with the 
Delta VPR envelope and CMV VSV-G packaging plasmids 
into actively growing HEK-293T using FuGENE 6 
transfection reagent as previously described (28). Virus 
containing supernatants were collected at 48 hours after 
transfection, filtered to eliminate cells, and target cells 
infected in the presence of 8 µg/ml polybrene. For all cell 
types, 24 hours after infection, the cells were split into 
fresh media, selected with 1 µg/ml puromycin. Five days 
post-infection, shRNA-expressing cells were analyzed or 
split again and analyzed 2-3 days later. All shRNA-
expressing cells were analyzed at 50-75% confluence.  
 
Cell Lysis and Immunoprecipitations 
All cells were rinsed with ice-cold PBS before lysis. All 
cells were lysed with Triton-X 100 containing lysis buffer 
(40 mM HEPES [pH 7.4], 2 mM EDTA, 10 mM sodium 
pyrophosphate, 10 mM sodium glycerophosphate, 150 mM 
NaCl, 50 mM NaF, 1% Triton-X 100, and one tablet of 
EDTA-free protease inhibitors [Roche] per 25 ml). The 
soluble fractions of cell lysates were isolated by 
centrifugation at 13,000 rpm for 10 min in a 
microcentrifuge. For measurement of the Rho-GTP loading 
state, Rho Assay Reagent was used according to the 
manufacturer’s protocol (Millipore). To observe gel mobility 
shifting in DEPTOR, 8% Tris Glycine gels (Invitrogen) 
were used. For all other applications, 4-12% Bis-Tris gels 
(Invitrogen) were used.  
 
cDNA Transfection 
To examine the effects of ROCK2 overexpression on 
endogenous S19 MLC2 phosphorylation, 500,000 HEK-
293T were plated in 6 cm culture dishes in DMEM/10% 
IFS. 24 hours later, cells were transfected with 1 µg of the 
indicated pRK5-based cDNA expression plasmids. All cells 
were lysed at 50-75% confluence 24 hours after 
transfection. 
 Immunofluorescence Assays  
25,000-100,000 cells were plated on fibronectin-coated 
glass coverslips in 12-well tissue culture plates, rinsed with 
PBS once and fixed for 15 minutes with 4% 
paraformaldehyde in PBS warmed to 37°C. The coverslips 
were rinsed three times with PBS and permeabilized with 
0.2% Triton X-100 in PBS for 15 minutes. After rinsing 
three times with PBS, the coverslips were blocked for one 
hour in blocking buffer (0.25% BSA in PBS), incubated 
with primary antibody in blocking buffer overnight at 4°C, 
rinsed twice with blocking buffer, and incubated with 
secondary antibodies (diluted in blocking buffer 1:1000) 
and/or Phalloidin for one hour at room temperature in the 
dark. The coverslips were then rinsed twice more in 
blocking buffer and twice in PBS, mounted on glass slides 
using Vectashield containing DAPI (Vector Laboratories), 
and imaged with a 10x or 63X objective using 
epifluorescence microscopy. Quantification of the 
percentage of p-H3 positive cells was performed with 
CellProfiler (www.cellprofiler.org) using 10x images. After 
illumination correction, the nuclei were automatically 
identified using the DAPI staining. P-H3 positive cells were 
defined by threshold intensity. The percentage of p-H3 
positive cells was then determined by the quotient of the 
total number of nuclei above that threshold intensity 
divided by total number of nuclei in the field.  
 
Live Cell Imaging  
HeLa cells were plated on glass-bottom dishes (MatTek). 
Cells were imaged with an ORCA-ER camera 
(Hammamatsu) attached to a Nikon TE2000 microscope. 
All images were collected, measured, and compiled with 
the aid of Metamorph imaging software (Molecular 
Devices) and Adobe Photoshop. For time-lapse imaging, 
cells were kept at 37°C with the aid of a Solent incubation 
chamber (Solent Inc.). 
 
Fluorescence Activated Cell Sorting 
Exponentially growing cells were treated as indicated, 
trypsinized, washed once in ice-cold PBS and fixed 
overnight in 1 ml 70% ethanol on ice. Cells were washed 
once in PBS and incubated in PBS containing 70 µM 
propidium iodide and 10 mg/ml RNAse A at 37°C for 
30 minutes. Flow cytometry analysis was performed using 
a Becton-Dickinson FACScan machine and CellQUEST 
DNA Acquisition software. 
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